Two-stage design and 'forced bioequivalence' [Two-Stage / GS Designs]

posted by Mikalai  – Belarus, 2018-06-06 06:28  – Posting: # 18854
Views: 2,802

(edited by Mikalai on 2018-06-06 06:44)

Dear all,
We plan to conduct a sequential (two stage) BE study, and I am concerned with "forced bioequivalence". Specifically, if we obtain non-equivalent results in the first stage with very low power and should recruit more volunteers, how can we protect ourselves from getting into "forced bioequivalence"? In other words, how can we differentiate between underpowered trials and non-equivalent results in the sequential BE? And how can we put this (protection against "forced bioequivalence") in the protocol not to raise many questions from regulators?
Any suggestions and advice will be appreciated.
Sincerely,
Mikalai

Complete thread:

Activity
 Admin contact
20,262 posts in 4,265 threads, 1,401 registered users;
online 24 (0 registered, 24 guests [including 18 identified bots]).
Forum time (Europe/Vienna): 21:48 UTC

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5